Where does Catalyst Pharmaceutical's cash flow data come from?

Every line is extracted from Catalyst Pharmaceutical's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	$221.32M+12.1%	$214.33M+30.8%	$217.56M+52.4%	$208.67M+206%	$197.35M+203%
Depreciation and amortization	$330K-22.5%	$375K-5.5%	$417K+13.6%	$451K+31.9%	$426K+27.9%
Stock-based compensation	$25.19M+26.9%	$24.78M+11.4%	$24.29M+13.9%	$23.04M+11.2%	$19.85M+1.3%
Deferred income taxes	——	——	——	——	——
Change in accounts receivable	$64.97M—	$66.4M—	$53.55M—	$14.09M—	——
Change in inventories	$15.62M—	$18.09M—	——	——	——
Change in accounts payable	——	——	——	-$1.59M-159%	$936K-86.4%
Change in accrued liabilities	$17.51M-59.1%	$24.16M-55.1%	$27.85M-47.6%	$34.66M-9.4%	$42.82M+156%
Change in other assets	——	——	$9.74M—	——	——
Amortization of intangible assets	$37.86M+1.3%	$37.5M+0.3%	$37.38M+0.8%	$37.38M+3.2%	$37.38M+5.7%
Net gains (losses) on investments	$3.08M-65.3%	$972K-80.8%	$4.33M+122%	$8.17M+2,240%	$8.86M+371%
Change in operating lease liabilities	-$410K-8.8%	-$401K-8.7%	-$393K-8.9%	-$385K-9.1%	-$377K-9.3%
Net cash from operating activities	$208.21M-22.3%	$208.67M-13.0%	$234.66M+4.5%	$275.09M+39.8%	$267.93M+63.9%
Capital expenditures	$85K-76.2%	$58K-89.6%	$114K-79.7%	$373K+1.9%	$357K+0.3%
Purchases of intangible assets	——	——	——	——	——
Purchases of equity securities	——	$0—	$0—	——	——
Acquired in-process research and development	——	$0—	$0—	——	——
Net cash from investing activities	-$85K+76.2%	-$58K+89.6%	-$114K+99.7%	-$373K+99.7%	-$357K+99.7%
Repurchases of common stock	$33.55M+430%	$25.3M—	$18.98M—	$12.65M—	$6.33M—
Proceeds from issuance of common stock	$3.3M—	$0—	——	——	——
Taxes paid for net share settlement	$1.43M—	$1.77M—	$1.33M—	——	——
Net cash from financing activities	-$32.93M-481%	-$16.99M-112%	$13.02M-90.8%	$8.37M-93.6%	$8.65M-93.3%
Net increase (decrease) in cash	$175.2M-35.2%	$191.62M-49.6%	$247.56M—	$277.11M—	$270.25M—
Interest paid	$503K-64.9%	$466K-66.6%	$430K-68.3%	$1.47M+74.0%	$1.43M—
Income taxes paid	$73.19M—	$71.99M—	$71.9M—	$73.59M—	——
Accretion Of Discount	$425K-59.4%	$350K-58.1%	$273K-56.1%	$1.26M+178%	$1.05M+171%
Amortization of capitalized software and acquired intangible assets	$37.86M+1.3%	$37.5M+0.3%	$37.38M+0.8%	$37.38M+3.2%	$37.38M+5.7%
Depreciation	$330K-22.5%	$375K-5.5%	$417K+13.6%	$451K+31.9%	$426K+27.9%
Equity Securities, FV-NI, Gain (Loss)	$3.08M-65.3%	$972K-80.8%	$4.33M+122%	$8.17M+2,240%	$8.86M+371%
Accrued expenses and other liabilities	$17.51M-59.1%	$24.16M-55.1%	$27.85M-47.6%	$34.66M-9.4%	$42.82M+156%
Increase (Decrease) in Deferred Income Taxes	——	——	——	——	——
Operating lease liabilities	-$410K-8.8%	-$401K-8.7%	-$393K-8.9%	-$385K-9.1%	-$377K-9.3%
Increase (Decrease) in Prepaid Expense and Other Assets	——	——	$9.74M—	——	——
Non Cash Change In Right Of Use Asset	$300K+6.4%	$295K+6.1%	$291K+6.2%	$287K+6.3%	$282K+6.0%
Payment Of Liabilities Arising From Asset Acquisition	$4.8M-63.0%	$4.59M-64.4%	$4.43M-65.1%	$13.24M+1.2%	$13M0.0%
Accrued Milestone Payment Classified As License And Acquired Intangibles Net	——	$12.5M—	$9.38M—	$6.25M—	$3.13M—
Increase Decrease In Operating Lease Liability	-$410K-8.8%	-$401K-8.7%	-$393K-8.9%	-$385K-9.1%	-$377K-9.3%
Free cash flow	$208.13M-22.2%	$208.61M-12.8%	$234.54M+4.7%	$274.72M+39.8%	$267.57M+64.1%
Free cash flow	$208.13M-22.2%	$208.61M-12.8%	$234.54M+4.7%	$274.72M+39.8%	$267.57M+64.1%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Catalyst Pharmaceutical's cash flow data come from?: Every line is extracted from Catalyst Pharmaceutical's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.